What are your Thoughts on Evrysdi (risdiplam)?
On Friday, August 7th, the FDA announced the approval of Evrysdi (Risdiplam), the first oral treatment for all types of SMA. BioNews frequently launches surveys to gauge the thoughts of community members. Your perspective may help better inform and improve how the medical industry treats people with SMA. Should this survey yield valuable insights, the results will be shared with the SMA community. This survey will take 2-3 minutes to complete. Your insights are appreciated.
Click here to take the survey
Log in to reply.